Telos Corporation
NASDAQ:TLSInformation Technology Services
-$0.01 today
- Market cap
- $544.88M
- Beta
- 0.97
- P/E (TTM)
- -12.4
- EPS (TTM)
- -$0.35
Volume 0.84M
Average 0.87M
TLS Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Telos CorporationNASDAQ: TLS
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development dips below year-ago levels
Q1 FY2026 research & development of $1.36M fell 13.6% year over year, behind the +9.4% change in trailing-twelve-month research & development. Sequentially, it fell 34.6% from the prior quarter. Over 3 fiscal years it compounded at -25.3% a year.
Context
- Research & development amounted to 4.3% of revenue in FY2025, down 3.5 pp from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -13.6% toward the trailing-twelve-month pace of +9.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 7.06M USD
- Year-over-year change
- -16.4%
- 4-year CAGR
- -22.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.06M | -16.4% |
| FY2024 | 2024-12-31 | 8.44M | -31.1% |
| FY2023 | 2023-12-31 | 12.25M | -27.6% |
| FY2022 | 2022-12-31 | 16.92M | -11.4% |
| FY2021 | 2021-12-31 | 19.1M | — |
Research & Development vs competitors
How TLS compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +9.4% is the 4th highest of 7, against a peer median of +9.0%.
- Research & development amounts to 3.8% of revenue for TLS, versus a peer median of 1.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $240M USD | +40.4% | -8.9% | 3.2% | |
| LTM Mar 2026 | $136.49M USD | +13.4% | +8.5% | 17.3% | |
| LTM Mar 2026 | $108.55M USD | +7.9% | -3.0% | 35.9% | |
| LTM Mar 2026 | $35.31M USD | +10.0% | -6.5% | 14.4% | |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥13.28M CNY | -94.8% | -61.3% | — |
| LTM Mar 2026 | $6.84M USD | +9.4% | -25.3% | 3.8% | |
| LTM Mar 2026 | $13K USD | -99.8% | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding TLS) | — | +9.0% | -6.5% | 1.6% | |
Competitors are the stored peer set for TLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 242.43M | 216.89M | 145.38M | 108.27M | 164.81M |
| Cost of Revenue | 156.4M | 137.84M | 92.44M | 73.84M | 103.79M |
| Gross Profit | 86.03M | 79.04M | 52.94M | 34.43M | 61.02M |
| Gross Margin | 35.5% | 36.4% | 36.4% | 31.8% | 37.0% |
| Research & Development | 19.1M | 16.92M | 12.25M | 8.44M | 7.06M |
| Selling, General & Admin | 108.4M | 115.98M | 81.01M | 75.49M | 78.93M |
| Operating Expenses | 127.49M | 132.89M | 93.26M | 90.3M | 85.53M |
| Depreciation & Amortization | 5.62M | 5.89M | 9.43M | 11.87M | 11.45M |
| EBITDA | (36.76M) | (46.61M) | (24.17M) | (39.98M) | (25.21M) |
| EBITDA Margin | -15.2% | -21.5% | -16.6% | -36.9% | -15.3% |
| Operating Income | (41.46M) | (53.85M) | (40.32M) | (55.87M) | (24.47M) |
| Operating Margin | -17.1% | -24.8% | -27.7% | -51.6% | -14.8% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 777K | 874K | 786K | 644K | 553K |
| Other Income / Expenses | (1.7M) | 476K | 5.93M | 3.38M | (12.74M) |
| Income Before Tax | (43.16M) | (53.37M) | (34.39M) | (52.49M) | (37.21M) |
| Pre-Tax Margin | -17.8% | -24.6% | -23.7% | -48.5% | -22.6% |
| Income Tax Expense | (28K) | 54K | 36K | 26K | (663K) |
| Net Income | (43.13M) | (53.43M) | (34.42M) | (52.52M) | (36.55M) |
| Net Margin | -17.8% | -24.6% | -23.7% | -48.5% | -22.2% |
| EPS (Basic) | (0.65) | (0.79) | (0.50) | (0.73) | (0.50) |
| EPS (Diluted) | (0.65) | (0.79) | (0.50) | (0.73) | (0.50) |
| Weighted Avg Shares | 66.37M | 67.56M | 69.26M | 71.85M | 72.88M |
| Weighted Avg Shares (Diluted) | 66.37M | 67.56M | 69.26M | 71.85M | 72.88M |
Telos Corporation
NASDAQ:TLS
Intrinsic Alpha fair value
Locked
Current Price
$7.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.